1.Health Economic Impact of First Pass Success: An Asia-Pacific Cost Analysis of the ARISE II Study
Leonard YEO ; Osama O. ZAIDAT ; Jeffrey L. SAVER ; Heinrich P. MATTLE ; Stephanie Hsiao Yu LEE ; Emilie KOTTENMEIER ; Heather L. CAMERON ; Rana A. QADEER ; Tommy ANDERSSON
Journal of Stroke 2021;23(1):139-143
2.Folic Acid in Stroke Prevention in Countries without Mandatory Folic Acid Food Fortification: A Meta-Analysis of Randomized Controlled Trials
Chia Yu HSU ; Shao Wen CHIU ; Keun Sik HONG ; Jeffrey L SAVER ; Yi Ling WU ; Jiann Der LEE ; Meng LEE ; Bruce OVBIAGELE
Journal of Stroke 2018;20(1):99-109
BACKGROUND AND PURPOSE: Additional folic acid (FA) treatment appears to have a neutral effect on reducing vascular risk in countries that mandate FA fortification of food (e.g., USA and Canada). However, it is uncertain whether FA therapy reduces stroke risk in countries without FA food fortification. The purpose of this study was to comprehensively evaluate the efficacy of FA therapy on stroke prevention in countries without FA food fortification. METHODS: PubMed, EMBASE, and clinicaltrials.gov from January 1966 to August 2016 were searched to identify relevant studies. Relative risk (RR) with 95% confidence interval (CI) was used as a measure of the association between FA supplementation and risk of stroke, after pooling data across trials in a random-effects model. RESULTS: The search identified 13 randomized controlled trials (RCTs) involving treatment with FA that had enrolled 65,812 participants, all of which stroke was reported as an outcome measure. After all 13 RCTs were pooled, FA therapy versus control was associated with a lower risk of any future stroke (RR, 0.85; 95% CI, 0.77 to 0.95). FA alone or combination of FA and minimal cyanocobalamin (≤0.05 mg/day) was associated with a lower risk of future stroke (RR, 0.75; 95% CI, 0.66 to 0.86) whereas combination of FA and cyanocobalamin (≥0.4 mg/day) was not associated with a lower risk of future stroke (RR, 0.95; 95% CI, 0.86 to 1.05). CONCLUSIONS: FA supplement reduced stroke in countries without mandatory FA food fortification. The benefit was found mostly in patients receiving FA alone or combination of FA and minimal cyanocobalamin.
Folic Acid
;
Food, Fortified
;
Humans
;
Outcome Assessment (Health Care)
;
Stroke
;
Vitamin B 12
3.Decision-Making Visual Aids for Late, Imaging-Guided Endovascular Thrombectomy for Acute Ischemic Stroke
Pouria MOSHAYEDI ; David S. LIEBESKIND ; Ashutosh JADHAV ; Reza JAHAN ; Maarten LANSBERG ; Latisha SHARMA ; Raul G. NOGUEIRA ; Jeffrey L. SAVER
Journal of Stroke 2020;22(3):377-386
Background:
and Purpose Speedy decision-making is important for optimal outcomes from endovascular thrombectomy (EVT) for acute ischemic stroke (AIS). Figural decision aids facilitate rapid review of treatment benefits and harms, but have not yet been developed for late-presenting patients selected for EVT based on multimodal computed tomography or magnetic resonance imaging.
Methods:
For combined pooled study-level randomized trial (DAWN and DEFUSE 3) data, as well as each trial singly, 100 person-icon arrays (Kuiper-Marshall personographs) were generated showing beneficial and adverse effects of EVT for patients with AIS and large vessel occlusion using automated (algorithmic) and expert-guided joint outcome table specification.
Results:
Among imaging-selected patients 6 to 24 hours from last known well, for the full 7-category modified Rankin Scale (mRS), EVT had number needed to treat to benefit 1.9 (interquartile range [IQR], 1.9 to 2.1) and number needed to harm 40.0 (IQR, 29.2 to 58.3). Visual displays of treatment effects among 100 patients showed that, with EVT: 52 patients have better disability outcome, including 32 more achieving functional independence (mRS 0 to 2); three patients have worse disability outcome, including one more experiencing severe disability or death (mRS 5 to 6), mediated by symptomatic intracranial hemorrhage and infarct in new territory. Similar features were present in person-icon figures based on a 6-level mRS (levels 5 and 6 combined) rather than 7-level mRS, and based on the DAWN trial alone and DEFUSE 3 trial alone.
Conclusions
Personograph visual decision aids are now available to rapidly educate patients, family, and healthcare providers regarding benefits and risks of EVT for late-presenting, imaging-selected AIS patients.
4.Platelet-Derived Growth Factor Is Associated with Progression of Symptomatic Intracranial Atherosclerotic Stenosis
Kyeong Joon KIM ; Sang Wuk JEONG ; Wi-Sun RYU ; Dong-Eog KIM ; Jeffrey L. SAVER ; Jong S. KIM ; Sun U. KWON ;
Journal of Clinical Neurology 2021;17(1):70-76
Background:
and Purpose We aimed to determine the relationships of 33 biomarkers of inflammation, oxidation, and adipokines with the risk of progression of symptomatic intracranial atherosclerotic stenosis (ICAS).
Methods:
Fifty-two of 409 patients who participated in the TOSS-2 (Trial of Cilostazol in Symptomatic Intracranial Stenosis-2) showed progression of symptomatic ICAS in magnetic resonance angiography at 7 months after an index stroke. We randomly selected 20 patients with progression as well as 40 age- and sex-matched control patients. We serially collected blood samples at baseline, 1 month, and 7 months after an index stroke. Multiplex analysis of biomarkers was then performed.
Results:
Demographic features and risk factors such as hypertension, diabetes, and smoking history were comparable between the two groups. Univariate analyses revealed that the levels of platelet-derived growth factor (PDGF)-AA [median (interquartile range)=1.64 (0.76–4.57) vs. 0.77 (0.51–1.71) ng/mL], PDGF-AB/BB [10.31 (2.60–25.90) vs. 2.35 (0.74–6.70) ng/mL], and myeloperoxidase [10.5 (7.5–22.3) vs. 7.8 (5.5–12.2) ng/mL] at 7 months were higher in the progression group. In the multivariate analysis using logistic regression, the PDGF AB/BB level at 7 months was independently associated with the progression of ICAS (p=0.02).
Conclusions
The PDGF-AB/BB level is associated with the progression of ICAS, and so may play a significant role in the progression of human ICAS.
5.Diffusion-Weighted Imaging-Alone Endovascular Thrombectomy Triage in Acute Stroke: Simulating Diffusion-Perfusion Mismatch Using Machine Learning
Yoon-Chul KIM ; Woo-Keun SEO ; In-Young BAEK ; Ji-Eun LEE ; Ha-Na SONG ; Jong-Won CHUNG ; Chi Kyung KIM ; Kyungmi OH ; Sang-il SUH ; Oh Young BANG ; Gyeong-Moon KIM ; Jeffrey L. SAVER ; David S. LIEBESKIND
Journal of Stroke 2022;24(1):148-151